Abstract 159P
Background
Malignant melanoma (MM) accounts for 80% of skin cancer-related deaths despite representing only 4% of cases. Immunotherapy has achieved promising results regarding recurrence-free survival (RFS) and overall survival (OS) in patients with MM. Thus, dendritic cell vaccination (DCvax) represents an anti-tumor autologous cell therapy with an excellent toxicity profile.
Methods
We designed a phase II trial to provide an autologous tumor lysate-loaded DCvax combined with immunomodulating radiotherapy (RT) and/or pre-leukapheresis IFN-α in patients (pts) with unresectable stage III or stage IV MM. Pts were randomised in 4 ARMS (Arm A: DCvax +RT; Arm B: DCvax + IFN-α; Arm C: DCvax +RT +IFN-α; Arm D: DCvax) to: a) determine the safety of the DCvax in combination with IFN-α and/or RT; b) select the regimen with the highest immune-related Disease Control Rate (irDCR) used in combination with DCvax; c) compare immunologic efficacy between the different treatment arms, defined as the proportion of subjects developing positive DTH to the Autologus Tumor Lysate (ATL) and/or KLH, along with tumour antigen-specific circulating immune effectors quantification at the baseline and after at least 4 DCvax doses. Furthermore, an in-depth study of DC recovery, functionality, and a full characterization of pt’s circulating immune profile was conducted. The findings were correlated with pt’s clinical outcome.
Results
Overall, 34 pts were enrolled from 2013 to the end of 2022, of whom only 29 were evaluable and fairly balanced for sex. Arm A pts (n=7): median age 65.8 years (yrs), OS 5.3 months (mos) (95% CI: 2.5-NR); arm B (n=8): age 54.8 yrs, OS 11.2 mos (1.2-NR); arm C (n=7): age 69.6 yrs, OS 8 mos (2-NR); arm D (n=7): age 66.9 yrs, OS 20.7 mos (11.7-NR). Notably, pts treated with the vaccine alone or with IFN-α pre-leukapheresis exhibited a positive DTH test in 83% and 71% of cases, respectively. Furthermore, the immune-related response to therapy observed in our cohort showed a higher irDCR in arm D (DCvax only) at 57% (p = 0.099).
Conclusions
We demonstrate the safety profile of DCvax in advanced MM pts and highlight unique immunomodulatory traits, paving the way for new therapeutic approaches combining immunotherapy and autologous cell therapies.
Clinical trial identification
EudraCT 2012-001410-41.
Legal entity responsible for the study
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy.
Funding
This work was partly supported thanks to the contribution of 5x1000 by the Italian Ministry of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract
146P - Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: A single-arm, single-center, phase II clinical trial
Presenter: Jinqiang Liu
Session: Poster Display session
Resources:
Abstract
147P - Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: A single-arm phase II trial
Presenter: Zixiang Wu
Session: Poster Display session
Resources:
Abstract
148P - Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
Presenter: JIE LIU
Session: Poster Display session
Resources:
Abstract
149P - Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: Kai Zhu
Session: Poster Display session
Resources:
Abstract
150P - Interim results of the multicenter phase II study on induction pembrolizumab plus chemotherapy followed by radiotherapy in locally advanced head and neck cancer
Presenter: Tatiana Antonova
Session: Poster Display session
Resources:
Abstract
151P - Anti-tumor T cell response and immunoselection under combined GARP:TGF-?1/PD-1 blockade
Presenter: Grégoire de Streel
Session: Poster Display session
Resources:
Abstract
152P - TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Presenter: Martin Forster
Session: Poster Display session
Resources:
Abstract
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Presenter: Cheng Xu
Session: Poster Display session
Resources:
Abstract
154P - Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Presenter: Aung Naing
Session: Poster Display session
Resources:
Abstract